Compare ARDX & BXMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARDX | BXMX |
|---|---|---|
| Founded | 2007 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | 2014 | N/A |
| Metric | ARDX | BXMX |
|---|---|---|
| Price | $7.99 | $14.76 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $12.95 | N/A |
| AVG Volume (30 Days) | ★ 6.3M | 205.6K |
| Earning Date | 02-19-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.24% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $398,234,000.00 | N/A |
| Revenue This Year | $22.65 | N/A |
| Revenue Next Year | $31.33 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 58.12 | N/A |
| 52 Week Low | $3.21 | $11.75 |
| 52 Week High | $8.17 | $13.75 |
| Indicator | ARDX | BXMX |
|---|---|---|
| Relative Strength Index (RSI) | 66.23 | 58.81 |
| Support Level | $6.73 | $14.40 |
| Resistance Level | $7.25 | $14.79 |
| Average True Range (ATR) | 0.57 | 0.14 |
| MACD | 0.14 | -0.01 |
| Stochastic Oscillator | 89.03 | 77.27 |
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Nuveen S&P 500 Buy-Write Income Fund is a diversified closed-ended management investment company based in the United States. Its investment objective is to seek attractive total returns with less volatility. The fund invests its managed assets in a diversified equity portfolio that seeks to substantially replicate price movements of the S&P 500 Index. It also uses an index options of writing (selling) index call options in seeking to moderate the volatility of returns relative to an all-equity portfolio. Its revenue is generated mainly from interest and dividend income.